Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsSUBCUTANEOUSStandard

TYENNE

TOCILIZUMAB-AAZG

Standard Dose
162MG/0.9ML
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary

Approval overview TYENNE is listed in Drugs@FDA under application 761449 (BLA).

Review priority: STANDARD Marketing status: Prescription Active ingredient TOCILIZUMAB-AAZG Form and strength INJECTABLE;SUBCUTANEOUS - 162MG/0.9ML Sponsor FRESENIUS KABI USA Submission history Latest submission status date: 2025-05-12 00:00:00.

Structured Monograph

Clinical summary

Approval overview TYENNE is listed in Drugs@FDA under application 761449 (BLA). Review priority: STANDARD Marketing status: Prescription Active ingredient TOCILIZUMAB-AAZG Form and strength INJECTABLE;SUBCUTANEOUS - 162MG/0.9ML Sponsor FRESENIUS KABI USA Submission history Latest submission status date: 2025-05-12 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Prescription
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.